

April 1, 2025

Dear All,

Company Name : Delta-Fly Pharma, Inc.  
(Code number : 4598 TSE Growth Market)  
Inquiries : Kenzo Iizuka, Senior Vice President, R&D  
(Contact : <https://www.delta-flypharma.co.jp/en/contactentrance/>)

Announcement of novel patent filing for the DFP-10917 drug product

The only worrying matter is the period of exclusive supply of DFP-10917 drug products for market launch when NDA approval of DFP-10917 in patients with R/R AML indication by the FDA in the USA. We are very excited to share a novel patent filing of the DFP-10917 drug product that was done to all PCT countries on March 27<sup>th</sup> and Taiwan on March 28<sup>th</sup> based upon our diligent work.

Our company own various global patents for DFP-10917 such as type I and type II crystalline substance, the induction of natural death of cancer cells through G2/M arrest in cell cycle with a favorable safety profile by a long-term and low-dose continuous infusion, and a DDS of DFP-10917 for tumor targeting.

The effective period of DFP-10917 related patents shall be extended to over 15 years for marketing launch by additional filing of a new patent. We are very excited to share that we invented a novel DFP-10917 drug product that has good stability for over 5 years.

In addition, a patent for combination therapy of DFP-10917 with Venetoclax filed it with all PCT countries and Taiwan. Patent was granted in Japan, USA, and Taiwan and effective over 15 years after this.

No effect on business operations.

END